Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1016/s1470-2045(22)00541-1

License

publisher-specific-oa